| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $10,200,046 ) |
| | 2025 | 2025 | THYMMUNE THERAPEUTICS INC | 215 1ST ST | CAMBRIDGE | MA | 02142-1213 | MIDDLESEX | USA | AY2AX000004 | Pluripotent stem cell-derived thymic epithelial cells to rescue athymic patients and reverse immunosenescence from thymic involution | 001 | 2 | NIH | 11/15/2024 | $0 |
| | 2025 | 2025 | THYMMUNE THERAPEUTICS INC | 215 1ST ST | CAMBRIDGE | MA | 02142-1213 | MIDDLESEX | USA | AY2AX000004 | Pluripotent stem cell-derived thymic epithelial cells to rescue athymic patients and reverse immunosenescence from thymic involution | 000 | 2 | NIH | 11/9/2024 | $10,200,046 |
|
| Issue Date FY: 2024 ( Subtotal = $1,000,000 ) |
| | 2024 | 2024 | THYMMUNE THERAPEUTICS INC | 700 MAIN ST | CAMBRIDGE | MA | 02139-3543 | MIDDLESEX | USA | R44AI170266 | Development of a stem-cell derived thymic cell therapy to treat patients with athymia | 000 | 3 | NIH | 2/23/2024 | $1,000,000 |
| | 2024 | 2023 | THYMMUNE THERAPEUTICS INC | 700 MAIN ST | CAMBRIDGE | MA | 02139-3543 | MIDDLESEX | USA | AY2AX000004 | Pluripotent stem cell-derived thymic epithelial cells to rescue athymic patients and reverse immunosenescence from thymic involution | 000 | 1 | NIH | 11/14/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $14,129,551 ) |
| | 2023 | 2023 | THYMMUNE THERAPEUTICS INC | 700 MAIN ST | CAMBRIDGE | MA | 02139-3543 | MIDDLESEX | USA | AY2AX000004 | Pluripotent stem cell-derived thymic epithelial cells to rescue athymic patients and reverse immunosenescence from thymic involution | 000 | 1 | NIH | 9/25/2023 | $13,842,822 |
| | 2023 | 2023 | THYMMUNE THERAPEUTICS, INC | 700 MAIN ST # 2P-6 | CAMBRIDGE | MA | 02139-3543 | MIDDLESEX | USA | R44AI170266 | Development of a stem-cell derived thymic cell therapy to treat patients with athymia | 000 | 2 | NIH | 3/21/2023 | $286,729 |
|
| Issue Date FY: 2022 ( Subtotal = $299,999 ) |
| | 2022 | 2022 | THYMMUNE THERAPEUTICS, INC | 700 MAIN ST # 2P-6 | CAMBRIDGE | MA | 02139-3543 | MIDDLESEX | USA | R44AI170266 | Development of a stem-cell derived thymic cell therapy to treat patients with athymia | 000 | 1 | NIH | 4/14/2022 | $299,999 |
|
|
